NCT06364501 - Phase 1 Trial of KH801 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2030

Conditions

Advanced Solid Tumors

Interventions

DRUG

KH801

KH801 is an injection solution

Trial Locations (4)

West China Second University Hospital,Sichuan University/West China Women's and Children's Hospital, Chengdu

Peking University Cancer Hospital, Beijing

Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou

Central Hospital Affiliated To Shandong First Medical University, Jinan

All Listed Sponsors

lead

Beijing Kanghong Biopharmaceutical Co., Ltd.

INDUSTRY